In 2025, the United States faces a dual crisis: record-breaking depression statistics and renewed attention on Ivermectin as an alternative healthcare option. This unexpected overlap underscores how patient demand, public trust, and health reform debates are reshaping the national conversation. Once associated primarily with pandemic-era disputes, ivermectin covid now...